In March 2022, KAI MedTech completed a more than 200 Million CNY of Series B+ financing led by SCGC and Shanghai LKC Investment, followed by Zhangjiang Haoheng Innovation Investment, Shanghai Sci-Tech Innovation Center Capital and Betta Fund, and the previous shareholder Hengxu Capital added investment.

In the past six months, under the background of tightening the overall environment and cooling the capital market, KAI MedTech was able to stand out from the fierce competition and complete two consecutive rounds of financing, which fully reflects the high recognition of KAI MedTech by the capital market. Previously, KAI MedTech has received investments from several funds, such as Hillhouse Capital, Hengxu Capital, SunMed Capital, and TF Capital and Tiger Yeah Capital, a Tigermed capital.